anondita medicare has secured a purchase order worth ₹2,92,41,000 from the Central Medical Services Society, Ministry of Health and Family Welfare (Government of India), for the supply of condoms. The order, dated June 16, 2026, is for the supply of Condoms SMO (Ustad Nirodh-HLL) [363]. The contract is valued at ₹2,92,41,000 and was disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Order Details

The purchase order (PO No: 10282600139/PDI/Domestic Fund-DF) was awarded by a domestic entity. The execution of the order is scheduled in two specific tranches. The first 50% of the order must be completed within 60 days from the date of the Purchase Order, while the remaining 50% is to be executed between 61 to 120 days from the date of the Purchase Order.

Contractual Terms

The disclosure confirms that all terms and conditions of the agreement signed by the company upon acceptance of the tender are applicable to this order. The company stated that neither the promoter group nor group companies hold any interest in the entity that awarded the order. Furthermore, the transaction does not fall within related party transactions.

Anondita Medicare Limited reported a strong financial performance for FY26, with revenue from operations increasing 78% year-on-year to ₹137.42 Cr. The company’s profit after tax (PAT) surged 107% to ₹34.30 Cr, while EBITDA grew 99% to ₹31.90 Cr. The growth was attributed to operational efficiency, a better product mix, and scale benefits, alongside successful expansion into international markets. Management expressed confidence in achieving a revenue target of ₹1,000 Cr within the next two years, driven by new capacity and global contracts.

The momentum continued into the second half of the fiscal year, with H2 FY26 revenue growing 82.77% YoY to ₹83.32 Cr. EBITDA for the half-year increased 99% to ₹31.89 Cr, and PAT rose 103% to ₹21.28 Cr. PAT margins improved to 25.54% during this period. The company operates 15 production lines with an annual capacity of approximately 806 million condoms, following a recent expansion from 562 million units.

Operational Highlights and Strategic Developments

FY26 was a transformational year for the manufacturer of condoms and sexual wellness products. The company successfully completed its IPO listing on the NSE SME platform and achieved several certifications, including MDSAP and SABS. Strategic vendor registrations were completed in Brazil and South Africa to cater to rising demand, with opportunities also emerging in Nepal, Uzbekistan, Cuba, Kenya, and the UAE.

A key milestone was the successful trial production of female condoms, a segment the company believes offers significant long-term growth potential due to increasing healthcare awareness and limited global manufacturing capacities. Anondita Medicare is the world's first company to register in Brazil for the supply of both female latex and non-latex condoms. The distribution network for the COBRA brand was also strengthened across 8 states, covering 4,569 retailers.

Future Outlook and Expansion Plans

Management outlined a roadmap to scale revenue to ₹1,000 Cr in two years, focusing on exports and female condoms. The company expects to secure a significant portion of the South African government tender, which requires 1 billion pieces annually over five years. Additionally, the firm aims to increase female condom capacity to 240 million pieces annually.

The company has invested ₹62 Cr in capex, with ₹24 Cr already spent to expand capacity by 307 million units. A further expansion of 250 million units is underway under work-in-progress, expected to add ₹325 Cr to turnover. Management highlighted that in-house patented machinery and packaging capabilities would drive margin improvements.

Financial Performance Summary

The company remains confident about sustaining its growth momentum, citing strong sector tailwinds, improving scale, and growing export opportunities.